# A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

> **NCT04213261** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Castle Creek Biosciences, LLC.** · enrollment: 6 (actual)

## Conditions studied

- Recessive Dystrophic Epidermolysis Bullosa

## Interventions

- **BIOLOGICAL:** FCX-007 (dabocemagene autoficel; see below for FCX-007 description)

## Key facts

- **NCT ID:** NCT04213261
- **Lead sponsor:** Castle Creek Biosciences, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-09
- **Primary completion:** 2023-01-17
- **Final completion:** 2037-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04213261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04213261, "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04213261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*